5 completed, 4 recruiting, 2 active not recruiting, 2 terminated. 6 Phase 2, 2 Early Phase 1, 2 Phase 4, 1 Not applicable, 1 Phase 1.
Follow Fluciclovine F18: new trials by email Literature Review of Fluciclovine F18 trials Research Report on Fluciclovine F18
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of Glioblastoma Fluciclovine F18 - Glioblastoma, Recurrent Glioblastoma | Early Phase 1 | Recruiting | Abramson Cancer Center at Penn Medicine | 15 | 2025-05-01 | 2026-09-09 |
| A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC) Biopsy Procedure, Biospecimen Collection, Chest Radiography - Stage II Nasopharyngeal Carcinoma AJCC v8, Stage III Nasopharyngeal Carcinoma AJCC v8 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 50 | 2024-06-25 | 2026-10-14 |
| Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging, Fluciclovine F18, Gadolinium-Chelate - Glioblastoma, IDH-Wildtype | Phase 2 | Recruiting | ECOG-ACRIN Cancer Research Group | 100 | 2024-04-11 | 2026-08-18 |
| Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study Biospecimen Collection, Bone Scan, Computed Tomography - Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma | Phase 2 | Active not recruiting | NRG Oncology | 194 | 2022-04-20 | 2026-08-17 |
| Fluciclovine and PSMA PET/CT for the Classification and Improved Staging of Invasive Lobular Breast Cancer Computed Tomography, Fluciclovine F18, Gallium Ga 68 Gozetotide - Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Lobular Carcinoma | Phase 1 | Completed | Emory University | 20 | 2021-07-16 | 2025-01-17 |
| Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging 3-Dimensional Conformal Radiation Therapy, Apalutamide, Computed Tomography - Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 3 | Recruiting | ECOG-ACRIN Cancer Research Group | 804 | 2020-10-08 | 2026-08-19 |
| 18F-fluciclovine PET/MRI Imaging for the Detection of Tumor Recurrence After Radiation Injury to the Brain Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Positron Emission Tomography, Fluciclovine F18 - Metastatic Intracranial Malignant Neoplasm, Recurrent Intracranial Neoplasm | Terminated | Mayo Clinic | 19 | 2020-08-18 | 2025-09-10 | |
| An Investigational Scan (18F-Fluciclovine PET-CT) for the Measurement of Therapeutic Response in Patients With Metastatic Prostate Cancer Computed Tomography, Fluciclovine F18, Positron Emission Tomography - Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 4 | Terminated | M.D. Anderson Cancer Center | 2 | 2019-09-19 | 2025-01-16 |
| Fluciclovine F18 or Ga68-PSMA PET/CT to Enhance Prostate Cancer Outcomes Computed Tomography, Fluciclovine F18, Gallium Ga68-labeled PSMA-11 - Prostate Adenocarcinoma | Phase 2 | Active not recruiting | Emory University | 140 | 2019-05-10 | 2026-09-02 |
| F18 Fluciclovine PET/CT in Assessing Tumor Volume and Radiation Therapy Response in Patients With Glioblastoma Undergoing Surgery Computed Tomography, Fluciclovine F18, Positron Emission Tomography - Glioblastoma | Not applicable | Completed | M.D. Anderson Cancer Center | 12 | 2019-04-30 | 2024-10-09 |
| Fluciclovine F18 PET/CT in Identifying the Origin of Head and Neck Squamous Cell Carcinoma in Patients With Metastatic Cervical Nodal Disease Computed Tomography, Fluciclovine F18, Positron Emission Tomography - Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Squamous Cell Carcinoma in Cervical Lymph Node | Early Phase 1 | Completed | M.D. Anderson Cancer Center | 16 | 2019-04-24 | 2024-03-28 |
| Gallium Ga 68-labeled PSMA-11 PET/CT and Fluciclovine F18 PET/CT in Imaging Participants With Recurrent Prostate Cancer After Surgery Computed Tomography, Fluciclovine F18, Gallium Ga 68-labeled PSMA-11 - Recurrent Prostate Carcinoma | Phase 2 | Completed | Jonsson Comprehensive Cancer Center | 50 | 2019-04-12 | 2020-10-14 |
| Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers. Fluciclovine F18 - Cervical Cancer, Endometrial Cancer | Phase 4 | Unknown | Bital Savir-Baruch | 30 | 2018-11-14 | 2020-02-28 |
| Fluciclovine F18 PET/CT Imaging in Assessing Hormone-Naive Men With Prostate Cancer That Has Spread to the Bone Computed Tomography, Fluciclovine F18, Positron Emission Tomography - Metastatic Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone | Phase 2 | Completed | University of Utah | 17 | 2018-10-02 | 2024-11-29 |
Prostatic Neoplasms (5) · Glioblastoma (3) · Brain Neoplasms (1) · Carcinoma, Lobular (1) · Carcinoma, Ovarian Epithelial (1) · Endometrial Neoplasms (1) · Nasopharyngeal Carcinoma (1) · Squamous Cell Carcinoma of Head and Neck (1) · Uterine Cervical Neoplasms (1)
M.D. Anderson Cancer Center (3) · ECOG-ACRIN Cancer Research Group (2) · Emory University (2) · Abramson Cancer Center at Penn Medicine (1) · Bital Savir-Baruch (1) · Jonsson Comprehensive Cancer Center (1) · Mayo Clinic (1) · NRG Oncology (1) · National Cancer Institute (NCI) (1) · University of Utah (1)
United States (14) · Canada (2) · Australia (1) · New Zealand (1) · Puerto Rico (1)
Ali Nabavizadeh, MD (1) · Ashesh Jani, MD, MSEE (1) · Bital Savir-Baruch, M.D (1) · Bridget F Koontz (1) · Daniel M. Trifiletti, MD (1) · Daniel P Barboriak (1) · David M Schuster, MD (1) · Gregory C Ravizzini (1) · Jason M Johnson (1) · Jeffrey Yap, PhD (1) · Johannes Czernin, M.D. (1) · Maria K Gule-Monroe (1) · Neha Vapiwala (1) · Robyn D Gartrell (1)
PMID 34081125, PMID 31216198, PMID 31375469, PMID 36549916, PMID 38421243, PMID 38976035, PMID 42377125
P30CA138292 (2), U10CA180820 (2), P30CA016672 (1), R01CA226992 (1), U10CA180868 (1), U10CA180886 (1)